Latest Janus kinase inhibitor Stories
Study demonstrates improvement in key disease measurements and disease-related symptoms with pacritinib treatment compared to best available therapy, regardless of platelet levels at the time of enrollment
INDIANAPOLIS, May 28, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) will host a webcast on June 11 to discuss data from the first two pivotal
-- Pacritinib Abstract #LBA7006 also to be Highlighted in the Official ASCO Press Program -- SEATTLE and DEERFIELD, Ill., April 22, 2015 /PRNewswire/ -- CTI BioPharma Corp.
SEATTLE, March 16, 2015 /PRNewswire/ -- CTI BioPharma Corp.
Trial Meets Primary Endpoint in Intent-to-Treat Population SEATTLE and DEERFIELD, Ill., March 9, 2015 /PRNewswire/ -- CTI BioPharma Corp.
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS, Dec.
-Significant synergy resulted with combination treatment of pacritinib and cytarabine or a MEK inhibitor- SEATTLE, Dec. 9, 2014 /PRNewswire/ -- CTI BioPharma Corp.
-Profile Supports Potential Role in Modulating Tumor Microenvironment in Blood-Related Cancers, Including AML, MDS, CMML and CLL- SEATTLE, Dec.
SEATTLE, Dec. 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.